A Phase I Study of BKM120, Administered Orally in Adult Chinese Patients With Advanced Solid Tumors

Trial Profile

A Phase I Study of BKM120, Administered Orally in Adult Chinese Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Buparlisib (Primary)
  • Indications Advanced breast cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis; Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 01 Nov 2016 Results published in the Anticancer Research
    • 11 Jan 2015 Status changed from active, no longer recruiting to completed.
    • 22 Jan 2014 Planned End Date changed from 1 Mar 2014 to 1 May 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top